IL162340A0 - Treating muscle wasting with selective androgen receptor modulators - Google Patents
Treating muscle wasting with selective androgen receptor modulatorsInfo
- Publication number
- IL162340A0 IL162340A0 IL16234002A IL16234002A IL162340A0 IL 162340 A0 IL162340 A0 IL 162340A0 IL 16234002 A IL16234002 A IL 16234002A IL 16234002 A IL16234002 A IL 16234002A IL 162340 A0 IL162340 A0 IL 162340A0
- Authority
- IL
- Israel
- Prior art keywords
- muscle wasting
- androgen receptor
- receptor modulators
- treating
- selective androgen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33618501P | 2001-12-06 | 2001-12-06 | |
PCT/US2002/036147 WO2003049675A2 (en) | 2001-12-06 | 2002-12-05 | Treating muscle wasting with selective androgen receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
IL162340A0 true IL162340A0 (en) | 2005-11-20 |
Family
ID=23314937
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16234002A IL162340A0 (en) | 2001-12-06 | 2002-12-05 | Treating muscle wasting with selective androgen receptor modulators |
IL162340A IL162340A (en) | 2001-12-06 | 2004-06-03 | Use of selective modulators for androgen receptor for the preparation of a drug for the treatment of muscle depletion |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL162340A IL162340A (en) | 2001-12-06 | 2004-06-03 | Use of selective modulators for androgen receptor for the preparation of a drug for the treatment of muscle depletion |
Country Status (21)
Country | Link |
---|---|
US (1) | US7547728B2 (pt) |
EP (2) | EP2289503B1 (pt) |
JP (2) | JP4605557B2 (pt) |
KR (1) | KR100767317B1 (pt) |
CN (1) | CN1617715B (pt) |
AT (1) | ATE526959T1 (pt) |
AU (1) | AU2002364949C1 (pt) |
BR (1) | BR0215115A (pt) |
CA (1) | CA2469340A1 (pt) |
CY (1) | CY1112509T1 (pt) |
DK (1) | DK1463497T3 (pt) |
EA (1) | EA007921B1 (pt) |
ES (1) | ES2372929T3 (pt) |
GE (1) | GEP20063984B (pt) |
HK (1) | HK1068102A1 (pt) |
HR (1) | HRP20040588A2 (pt) |
IL (2) | IL162340A0 (pt) |
MX (1) | MXPA04005519A (pt) |
PT (1) | PT1463497E (pt) |
TW (1) | TWI339118B (pt) |
WO (1) | WO2003049675A2 (pt) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090264534A1 (en) * | 1996-11-27 | 2009-10-22 | Dalton James T | Selective androgen receptor modulators |
US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US7518013B2 (en) | 2000-08-24 | 2009-04-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US8008348B2 (en) * | 2001-12-06 | 2011-08-30 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
US20040260108A1 (en) * | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
US8853266B2 (en) * | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
EP2289503B1 (en) * | 2001-12-06 | 2016-06-29 | University of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
BRPI0307699A2 (pt) | 2002-02-07 | 2015-06-16 | Gtx Inc | Tratamento de hiperplasia benigna da próstata com sarms. |
GEP20074209B (en) * | 2002-02-28 | 2007-10-10 | , | Multi-substitued selective androgen receptor modulators and methods of use thereof |
EP2266577B8 (en) * | 2002-02-28 | 2015-01-21 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
US7803970B2 (en) | 2002-02-28 | 2010-09-28 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
US7705182B2 (en) | 2002-02-28 | 2010-04-27 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
JP3777481B2 (ja) * | 2002-08-19 | 2006-05-24 | 財団法人名古屋産業科学研究所 | 球脊髄性筋萎縮症の病態を再現する非ヒト動物、及び球脊髄性筋萎縮症治療剤 |
AU2003287077B2 (en) * | 2002-10-15 | 2007-09-20 | University Of Tennessee Research Foundation | Methylene-bridged selective androgen receptor modulators and methods of use thereof |
US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
CN1726020A (zh) * | 2002-10-16 | 2006-01-25 | Gtx公司 | 用sarm治疗老年男性雄激素缺乏(adam)相关的疾病 |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
DE602004026583D1 (de) * | 2003-06-27 | 2010-05-27 | Orion Corp | Als androgenrezeptormodulatoren geeignete propionamidderivate |
FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
CN100462353C (zh) * | 2003-06-27 | 2009-02-18 | 奥赖恩公司 | 用作雄激素受体调节剂的丙酰胺衍生物 |
EA013738B1 (ru) * | 2003-10-14 | 2010-06-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Лечение нарушений костной ткани с использованием селективных модуляторов адрогенных рецепторов |
EP1631540A4 (en) * | 2003-12-16 | 2006-10-04 | Gtx Inc | PRODRUGS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD OF USE THEREOF |
US7507860B2 (en) * | 2004-04-13 | 2009-03-24 | Pfizer Inc. | Androgen modulators |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
GEP20094851B (en) * | 2004-06-07 | 2009-12-10 | The Univ Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US9889110B2 (en) * | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US7601725B2 (en) | 2004-07-16 | 2009-10-13 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as Aurora kinase inhibitors |
US7655700B2 (en) * | 2005-08-25 | 2010-02-02 | Michigan State University | Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles |
JP2009506119A (ja) * | 2005-08-31 | 2009-02-12 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置 |
MX2009000385A (es) * | 2006-07-12 | 2009-04-06 | Univ Tennessee Res Foundation | Acil-anilidas sustituidas y metodos de uso de las mismas. |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
EA016853B1 (ru) | 2006-08-24 | 2012-08-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Замещенные ациланилиды и их применение |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US8420694B2 (en) | 2007-08-07 | 2013-04-16 | Takeda Pharmaceutical Company Limited | Pyrrolidin-2-one derivatives as androgen receptor modulator |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
KR20170001736A (ko) * | 2007-09-11 | 2017-01-04 | 지티엑스, 인코포레이티드 | 고형의 선택적인 안드로겐 수용체 모듈레이터 |
CA2709677C (en) | 2007-12-21 | 2017-03-14 | Lin Zhi | Selective androgen receptor modulators (sarms) and uses thereof |
US11090313B2 (en) | 2010-05-20 | 2021-08-17 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
JP5808797B2 (ja) | 2010-05-20 | 2015-11-10 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 筋萎縮を阻害するための方法 |
WO2012071340A1 (en) | 2010-11-23 | 2012-05-31 | Metamagnetics Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
AU2012268036B2 (en) | 2011-06-06 | 2017-04-06 | THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS | Methods of inhibiting muscle atrophy |
US20140371188A1 (en) * | 2011-11-23 | 2014-12-18 | University Of Iowa Research Foundation | Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy |
US20150057452A1 (en) * | 2012-04-04 | 2015-02-26 | Catylix, Inc. | Selective androgen receptor modulators |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
DK2872482T3 (da) | 2012-07-13 | 2020-09-21 | Oncternal Therapeutics Inc | En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
JP2015071549A (ja) * | 2013-10-02 | 2015-04-16 | 株式会社ファンケル | アトロジン−1抑制剤 |
US10441567B2 (en) | 2014-01-17 | 2019-10-15 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
CA2964371A1 (en) * | 2014-10-16 | 2016-04-21 | Gtx, Inc. | Methods of treating urological disorders using sarms |
KR101919081B1 (ko) * | 2017-05-11 | 2018-11-16 | (주)녹십자웰빙 | 인간 태반 추출물을 유효성분으로 포함하는 근 위축증 또는 근육감소증의 예방 또는 치료용 및 근육 기능 개선용 조성물 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1360001A (en) | 1971-06-16 | 1974-07-17 | Scherico Ltd | Pharmaceutical compositions comprising substituted anilides |
US3875229A (en) * | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
JPS6044294B2 (ja) | 1976-04-15 | 1985-10-02 | 帝国臓器製薬株式会社 | アニリド誘導体 |
US4139638A (en) * | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
EP0002309B1 (en) * | 1977-10-12 | 1982-12-01 | Imperial Chemical Industries Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
US4191775A (en) * | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
NZ197008A (en) | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
US4336505A (en) * | 1980-07-14 | 1982-06-22 | John Fluke Mfg. Co., Inc. | Controlled frequency signal source apparatus including a feedback path for the reduction of phase noise |
JPS57171904A (en) * | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
ATE28864T1 (de) * | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
US4633025A (en) | 1985-04-15 | 1986-12-30 | Miles Laboratories, Inc. | Method for preparing (+)R-2-methyl-hexane-1,2-diol |
GB8617653D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
GB8617652D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
US5162504A (en) * | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US5847076A (en) * | 1993-05-20 | 1998-12-08 | Board Of Regents, The University Of Texas System | Regulators of the proteasome |
CA2181358A1 (en) | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
US5609849A (en) * | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
WO1998005962A1 (en) | 1996-08-02 | 1998-02-12 | Panvera Corporation | A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization |
US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
US6995284B2 (en) * | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US6492554B2 (en) * | 2000-08-24 | 2002-12-10 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
WO1998053826A1 (en) * | 1997-05-30 | 1998-12-03 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
WO1998055153A1 (en) | 1997-06-04 | 1998-12-10 | The University Of Tennessee Research Corporation | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
JP2003511467A (ja) | 1999-10-14 | 2003-03-25 | ブリストル−マイヤーズ スクイブ カンパニー | アンドロゲンレセプターリガンド結合ドメインの結晶構造 |
HUP0203785A2 (hu) | 1999-10-19 | 2003-04-28 | Nobex Corporation | Eljárás Casodex enantiomereinek, származékainak és intermediereinek előállítására |
BR0015124A (pt) | 1999-10-27 | 2002-07-02 | Nobex Corp | Método de preparação de um enanciÈmero substancialmente puro |
US20030069215A1 (en) * | 2001-03-30 | 2003-04-10 | The Government Of The United States Of America, | Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate |
EP1299094A2 (en) | 2000-06-28 | 2003-04-09 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
EP1401801B1 (en) * | 2000-08-24 | 2006-11-02 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
EP2289503B1 (en) * | 2001-12-06 | 2016-06-29 | University of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
FI20030958A0 (fi) | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
-
2002
- 2002-12-05 EP EP10075696.4A patent/EP2289503B1/en not_active Expired - Lifetime
- 2002-12-05 PT PT02802565T patent/PT1463497E/pt unknown
- 2002-12-05 AT AT02802565T patent/ATE526959T1/de active
- 2002-12-05 EP EP02802565A patent/EP1463497B1/en not_active Expired - Lifetime
- 2002-12-05 US US10/310,150 patent/US7547728B2/en not_active Expired - Fee Related
- 2002-12-05 ES ES02802565T patent/ES2372929T3/es not_active Expired - Lifetime
- 2002-12-05 KR KR1020047008659A patent/KR100767317B1/ko active IP Right Grant
- 2002-12-05 CN CN028279050A patent/CN1617715B/zh not_active Expired - Fee Related
- 2002-12-05 MX MXPA04005519A patent/MXPA04005519A/es active IP Right Grant
- 2002-12-05 JP JP2003550726A patent/JP4605557B2/ja not_active Expired - Fee Related
- 2002-12-05 EA EA200400774A patent/EA007921B1/ru not_active IP Right Cessation
- 2002-12-05 IL IL16234002A patent/IL162340A0/xx unknown
- 2002-12-05 WO PCT/US2002/036147 patent/WO2003049675A2/en active IP Right Grant
- 2002-12-05 AU AU2002364949A patent/AU2002364949C1/en not_active Ceased
- 2002-12-05 DK DK02802565.8T patent/DK1463497T3/da active
- 2002-12-05 CA CA002469340A patent/CA2469340A1/en not_active Abandoned
- 2002-12-05 GE GE5641A patent/GEP20063984B/en unknown
- 2002-12-05 BR BR0215115-4A patent/BR0215115A/pt not_active Application Discontinuation
- 2002-12-06 TW TW091136268A patent/TWI339118B/zh not_active IP Right Cessation
-
2004
- 2004-06-03 IL IL162340A patent/IL162340A/en not_active IP Right Cessation
- 2004-06-24 HR HR20040588A patent/HRP20040588A2/hr not_active Application Discontinuation
-
2005
- 2005-02-22 HK HK05101487.3A patent/HK1068102A1/xx not_active IP Right Cessation
-
2010
- 2010-07-23 JP JP2010165864A patent/JP2010254707A/ja active Pending
-
2012
- 2012-01-04 CY CY20121100004T patent/CY1112509T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1068102A1 (en) | Treating muscle wasting with selective androgen receptor modulators | |
HK1066471A1 (en) | Oxyntomodulin for preventing or treating excess weight | |
IL160208A0 (en) | Amidine derivatives for treating amyloidosis | |
ZA200503967B (en) | Agent for preventing or treating neuropathy | |
HK1047887B (zh) | 氨基酸的四氫噻唑-或四氫化吡咯衍生物作為抗高血糖劑的應用 | |
MXPA03007140A (es) | Derivados de carbolina. | |
ZA200200619B (en) | Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof. | |
WO2001044247A3 (en) | Agents and methods for the treatment of proliferative diseases | |
EP1465968A4 (en) | METHODS OF TREATING DISTILLATE DEODORIZER | |
AU4314199A (en) | Compounds, compositions and methods for treating erectile dysfunction | |
PL368556A1 (en) | Methods for treating or preventing skin disorders using cd2-binding agents | |
BR0017157A (pt) | Derivados de 6-hidroxi-indazol para o tratamento de glaucoma | |
MXPA04007391A (es) | Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes. | |
AU2002232400A1 (en) | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis | |
HK1047239A1 (en) | Concomitant drugs for treating glaucoma | |
EP1450807A4 (en) | PROCESS FOR TREATING DEPRESSION WITH DELTA RECEPTOR AGONIST COMPOUNDS | |
HUP0303243A3 (en) | Carbamate compounds for use in preventing and treating bipolar disorder | |
PL358296A1 (en) | 5ht2 agonists for controlling iop and treating glaucoma | |
EP1448193A4 (en) | THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS | |
MY122838A (en) | Treating allergic and inflammatory conditions | |
DK3103443T3 (da) | Fremgangsmåde til behandling af primær søvnforstyrrelse | |
EP1419236A4 (en) | METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS | |
PL365021A1 (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
EP1458694A4 (en) | THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEAMIC CONDITIONS | |
HK1050897A1 (en) | Pyranoindoles for treating glaucoma |